BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD
19 September 2022 - 7:30AM
Business Wire
- Obtaining regulatory approval opens the door to the
availability of SoloSmart® in the European Union
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French
company specialized in the design, development, and manufacturing
of innovative medical devices, and SANOFI announced the completion
of the development of SoloSmart® today, on the opening of the EASD
(European Association for the Study of Diabetes) annual meeting in
Stockholm, Sweden. SoloSmart® is fully compatible with the
pharmaceutical group's SoloStar® injection pens.
The result of the collaboration initiated in 2019 between the
two companies is presented as an accessory to the Sanofi SoloStar®/
DoubleStar® insulin pens, which records information about the
insulin dose, time and date of each injection and transmits it via
Bluetooth to a compatible mobile application. The SoloSmart® device
automatically and accurately records injected doses, eliminating
the need for manual logbooks and possibly allows for adapting to
new patient uses of continuous glucose monitoring systems or
connected BGM.
Developed by BIOCORP's R&D department, SoloSmart® meets the
latest requirements of the new European medical device regulation.
Its commercial launch will begin early 2023 in the distribution
networks approved by SANOFI and its partners. This partnership
strategic step validates a substantial milestone - more details
will be given on September 29th (half year results).
Eric Dessertenne, CEO of BIOCORP, said: "The expertise we have
developed with Mallya leads us to improve and develop a new device
by miniaturizing it, keeping data reliability. We are today very
proud of developments achieved by our respective R&D and to
present them today at the EASD, which brings together an
international diabetes community. The strength of this industrial
and commercial partnership has resulted in a technological
achievement which will allow people living with diabetes, users of
SoloStar® pens, to benefit from a solution that improves their
daily life thanks to a presentation that is very compact but still
secure and accurate.”
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR).
For more information, please visit www.biocorpsys.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220918005029/en/
CONTACTS BIOCORP Jacques Gardette Chairman of the Board
Éric Dessertenne Chief Executive Officer
Sylvaine Dessard Marketing & Communication Director
rp@biocorp.fr + 33 (0)6 88 69 72 85
CONTACTS ULYSSE COMMUNICATION Bruno ARABIAN
barabian@ulysse-communication.com +33 (0)6 87 88 47 26
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Apr 2023 bis Apr 2024